NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) announced positive biomarker findings from its Phase 2, randomized, double-blind, placebo-controlled proof-of-concept RoAD study (NST-AD-001) of PrimeC in Alzheimer’s disease (AD).
The plasma biomarker analysis showed multiple, distinctive protein biomarker changes.
The biomarker findings supporting PrimeC’s target engagement build on its previously reported favorable safety and tolerability profile from RoAD, in which no serious adverse events and no new or unexpected safety signals were identified.
